Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Heart failure; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms HELP
  • Sponsors Tenax Therapeutics

Most Recent Events

  • 13 Aug 2024 According to a Tenax Therapeutics media release, the company hosted "LEVEL Setting" - a scientific roundtable exploring the rationale for TNX-103 (oral levosimendan) in the treatment of PH-HFpEF. In this event "Review of data from the Phase 2 HELP Study" was presented by Barry Borlaug, M.D. from Mayo clinic.
  • 30 Apr 2024 According to a Tenax Therapeutics media release, the patents covering the use of IV and oral levosimendan for the treatment of PH-HFpEF rely on key discoveries Tenax Therapeutics made with the HELP Study.
  • 09 Apr 2024 According to a Tenax Therapeutics media release, presentation of review of data from the Phase 2 HELP Study by Barry Borlaug, M.D. (Mayo Clinic), will explore this most prevalent type of pulmonary hypertension and the therapeutic potential of levosimendan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top